Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8

Read more at globenewswire.com